Clinical Trials Express:Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT) | Zendy

Toshitaka Nakamura | Zendy; Toshio Matsumoto | Zendy; Toshitsugu Sugimoto | Zendy; Takayuki Hosoi | Zendy; Takami Miki | Zendy; Itsuo Gorai | Zendy; Hideki Yoshikawa | Zendy; Yoshiya Tanaka | Zendy; Sakae Tanaka | Zendy; Teruki Sone | Zendy; Tetsuo Nakano | Zendy; Masako Ito | Zendy; Shigeyuki Matsui | Zendy; Toshiyuki Yoneda | Zendy; Hideo Takami | Zendy; Ko Watanabe | Zendy; Taisuke Osakabe | Zendy; Masataka Shiraki | Zendy; Masao Fukunaga | Zendy

Open Access

Clinical Trials Express:Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)

Author(s) -

Toshitaka Nakamura,

Toshio Matsumoto,

Toshitsugu Sugimoto,

Takayuki Hosoi,

Takami Miki,

Itsuo Gorai,

Hideki Yoshikawa,

Yoshiya Tanaka,

Sakae Tanaka,

Teruki Sone,

Tetsuo Nakano,

Masako Ito,

Shigeyuki Matsui,

Toshiyuki Yoneda,

Hideo Takami,

Ko Watanabe,

Taisuke Osakabe,

Masataka Shiraki,

Masao Fukunaga

Publication year - 2014

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2013-4175

Subject(s) - denosumab , medicine , placebo , osteoporosis , hazard ratio , clinical endpoint , randomized controlled trial , adverse effect , incidence (geometry) , confidence interval , surgery , pathology , alternative medicine , physics , optics

Denosumab 60 mg sc injection every 6 months for 36 months was well tolerated and effective in reducing the incidence of vertebral, nonvertebral, and hip fracture in predominantly Caucasian postmenopausal women with osteoporosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research